🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

[LYSA - ASH 24] 📢 Presentation by Vincent Camus at ASH on GAINED, a LYSA study Find other LYSA presentations here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

[LYSA - ASH 24] 📢 Presentation by Sydney Dubois at ASH Find other LYSA presentations here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

[LYSA posters ASH 24] 📢 7 posters this Monday at ASH by Emmanuel Bachy, Vincent Camus, Yannick Le Bris, Amira Marouf, Jean-Marie Michot, Roch Houot and Bertrand Arnulf. Find out more here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

[LYSA - ASH 24] 📢 Presentation by Steven Le Gouill at ASH on Oasis II, a LYSA study Find other LYSA presentations here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

Le Gouill - OASIS II • IBR + R v I-Ven-R 1L MCL • DDPCR for MRD at 6mo • MRD- rate 82% with IVR, higher than any other regimen incl immunochemo • some excess AE: diarrhoea, neutrop, arrhyth IVR clearly a hugely active triplet #ASH24 #lymsm

[LYSA - ASH 24] 📢 Presentation by @SRoulland at ASH Find other LYSA presentations here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

[LYSA - ASH 24] 📢 Presentation by Cedric Rossi at ASH Find other LYSA presentations here: urlr.me/x5ABjz Stay tuned! #ASH24 #lymphoma #study #congress

[LYSA congress] 📷A look back at these few days at the 66th annual meeting of ASH 💡 LYSA present 20 abstracts : urlr.me/RZqz6B Great opportunity to exchange ideas with lymphoma specialists from all over the world! #ASH2024 #Hematology #Lymphoma

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). nature.com/articles/s4159…

Here is another remarkable study by the Lysa Lymphoma, published in HemaSphere Journal (IF = 11.9)! It evaluates the efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma with matched cohort analysis. Kudos to Amira Marouf for leading this collaborative work. onlinelibrary.wiley.com/doi/full/10.10…

Insightful annual gathering of the IELSG in Stresa. At-a-glance: MZL, PMBL, CNSL, NKTCL, lots of ongoing interventional trials and PET/translational studies With colleagues from: FIL_ETS Lysa Lymphoma SAKK GELTAMO UK NCRI, Poland, China, Brazil… Cc ICML Conference C. Thieblemont

[LYSA - SFH 23] 📢 Le LYSA est présent au 45ème congrès de la SFH du 02 au 04 avril 2025. Retrouvez-nous pour discuter des avancées majeures et des dernières innovations en matière de prise en charge des patients atteints de lymphomes. 📌 Au programme : - 2 sessions LYSA : une

[LYSA - SFH 25] 📷 Retour en images sur le 45ème congrès de la SFH. 🌐 Redécouvrez toutes les présentations LYSA ici : urls.fr/AUyp00 #SFH25 #lymphoma #study #congress #congres #etudes

[LYSA - Publication] 💡 Une étude prospective de phase 2, pilotée par le Lysa Lymphoma et coordonnée par le LYSARC, vient d’être publiée dans Nature Cancer Elle démontre l’efficacité du glofitamab dans cette situation clinique complexe 🧪 47 patients atteints de DLBCL en

Thank you VJHemOnc for giving me the opportunity to discuss the findings of our recent publication in Nature Medicine: nature.com/articles/s4159… #CARTcell #EBMT25 Lysa Lymphoma

Proud of C. Thieblemont for chairing the #ICML18 plenary session, along with franco cavalli Cc Hôpital Saint-Louis AP-HP Lysa Lymphoma ICML Conference

To refine MZL classification, we developed RECLASS, an algorithm-based system harmonizing histological and clinical criteria. Next steps: prognostic analysis, external validation. Looks promising 🤩! #ICML18 #REALYSA ⁦Lysa Lymphoma⁩ onlinelibrary.wiley.com/doi/10.1002/ho…

Adding drugs to SOC not always mean efficacy improvement & may impact safety! Tazemetostat-R-CHOP as 1L in HR follicular #lymphoma didn't show clear signal of superiority over standard CIT. And... ⚠️ 5 SPM: 1 prostate, 1 colon, 3 AML Phase II by Lysa Lymphoma #ICML2025 #18ICML

An important effort was made by Lysa Lymphoma investigators to demonstrate feasibility of associating ctDNA + PET in EOT assessment in 1L PMBL and 1L FL. Congrats to Vincent Camus and Alexis Claudel 🎉 Proud of you guys!! #ICML18

TCHR DLBCL and outcomes either antiCD19 CART no very good outcomes what is there anything else available? PD-1 inhibition did not affect outcomes DESCAR-T Lysa Lymphoma